Patients had a small but nonsignificant survival advantage when continuing with anti-VEGF therapy in the second-line instead ...

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a ...

Biocon Biologics receives Health Canada approval for Yesafili, the first Eylea biosimilar in Canada, with launch slated for ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...

New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 ...

The prototypical angiogenic factor vascular endothelial growth factor A (VEGFA) released by leukaemic cells (green fluorescent protein + cells in (a) and infiltrating cells in (b)) activates the ...

New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 ...

Biocon said that its subsidiary Biocon Biologics has received a notice of compliance (NOC) for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe ...

Bengaluru: Biocon Biologics Ltd ., a fully integrated global biosimilars company and a subsidiary of Biocon Ltd ., has ...

The Department of Ophthalmology’s annual Buffalo Ophthalmology Symposium at the Jacobs School of Medicine and Biomedical Sciences featured both a glance back at the department’s history and an eye to ...